Skip to main content

Table 3 Patient characteristics during ICU stay

From: Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilator-associated pneumonia

 

Subsequent VAP

P-value

 

Yes n = 17

No n = 105

 

At VAT diagnosis

   

Duration of prior mechanical ventilation, d

8 (3, 18)

11 (6, 17)

0.689

Prior antibiotic treatment

11 (64)

68 (64)

>0.999

SOFA score

6 (6, 9)

4 (3, 7)

0.029

∆PaO2/FiO2

10 (-30, 50)

-12 (-66, 39)

0.221

Temperature

38 (37.5, 38.6)

38 (37.6, 38.4)

0.829

Leucocytes

13.4 (10, 18.9)

10.6 (7.2, 14.6)

0.034

PCT

1.1 (0.7, 1.85)

0.55 (0.22, 3)

0.515

CRP

52 (18, 135)

60 (14, 126)

0.825

Antibiotic treatment

  

0.002

  No

13 (76)

35 (33)

 

  Yes

4 (23)

70 (66)

 

  Appropriate

2 (11)

56 (53)

 

  Inappropriate

2 (11)

14 (13)

 

During ICU stay

   

Tracheostomy

5 (29)

33 (31)

>0.999

Duration of antibiotic treatment, d

18 (15, 22)

18 (11, 30)

0.819

Percentage of days in the ICU with antimicrobials

48 (0, 70)

51 (0, 70)

0.595

Duration of mechanical ventilation, d

27 (16, 29)

22 (13, 35)

0.553

Length of ICU stay, d, mean ± SD

43 ± 50

32 ± 21

0.137

ICU mortality

9 (52)

37 (35)

0.185

  1. Data are n (%) or median (25th, 75th IQR), unless otherwise specified. SOFA, sequential organ failure assessment; PCT, procalcitonin; CRP, C-reactive protein; VAT, ventilator-associated pneumonia; ∆PaO2/FiO2: difference in arterial partial pressure of oxygen/inspired oxygen fraction.